(A) Incorporation of random sequences for degenerate primers used to molecularly tag each DNA molecule. Each “N” can be either A, C, G, or T and is chosen randomly during synthesis. (B) Schema of Safe-SeqS (adapted with permission from Proceedings of the National Academy of Sciences of the USA; ref. 84). Clinically relevant mutations are present at very low frequency in patient samples. Barcoding of DNA can improve the signal-to-noise ratio in NGS analysis, because mutant tumor alleles containing the same UID will be amplified, whereas random errors resulting from PCR amplification will remain at low frequency.